Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3) - Concepedia

Concepedia

Publication | Open Access

Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3)

DOI Full Paper Access

53

Citations

13

References

2016

Year

Kristian Reich, Craig L. Leonardi, Mark Lebwohl, Francisco A. Kerdel, Yukari Okubo, Ricardo Romiti, Orin M. Goldblum, Ellen B. Dennehy, Lisa Kerr, Howard Sofen

Journal of Dermatological Treatment

Abstract

Ixekizumab was efficacious in treating scalp psoriasis in patients with moderate-to-severe psoriasis, with most patients achieving complete or near-complete resolution of scalp psoriasis and maintaining this response over 60 weeks.

References

	Year	Citations

Page 1